← FDA DRUG APPROVALS

FDA BLA · BLA761310

ELAHERE

mirvetuximab soravtansine

Sponsor: IMMUNOGEN INC

APPLICATION
BLA761310
TYPE
BLA
ORIGINAL APPROVAL
2022-11-14
LATEST ACTION
2025-07-14
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

ELAHEREPrescription
MIRVETUXIMAB SORAVTANSINE-GYNX 100mg/20mL single-dose vial · INJECTABLE · INJECTION

Approval history

2025-07-14Labeling · Supplement 10 · standardAP
2024-03-22Efficacy · Supplement 5 · priorityLabelAP
2022-11-14Type 1 - New Molecular Entity · Original · priorityLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →